Alliance Pharma PLC Grant of Options to Directors (1320D)

TIDMAPH

RNS Number : 1320D

Alliance Pharma PLC

05 October 2018

5 October 2018

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Grant of Options to Directors

Alliance Pharma plc (AIM: APH), the international specialty pharmaceutical group, announces that the Board has issued options over an aggregate of 1,428,000 ordinary shares of 1 pence each in the Company ("Share Options"), on the recommendation of the Company's Remuneration Committee, to the Directors detailed below.

Peter Butterfield, Chief Executive Officer, has been awarded a total of 1,250,000 Share Options. 1,000,000 Share Options have been granted to Mr Butterfield in connection with his appointment on 1 May 2018 as CEO and in recognition of the additional responsibilities that he has assumed. 250,000 have been granted under the Company's 2015 Unapproved Share Option Plan.

Andrew Franklin, Chief Financial Officer, has been awarded a total of 178,000 Share Options pursuant to the Company's 2015 Unapproved Share Option Plan.

The Share Options granted all have an exercise price of 81.6p, being the closing mid-market price on 19 September 2018, the date of announcement of the Company's half year results for 2018, and become exercisable on 19 September 2021, being the third anniversary of the date of the grant, subject to continued employment and the satisfaction of certain performance conditions measured by growth targets in the Company's diluted earnings per share over that three year period.

The net effect of the grant of Share Options and the resultant option holdings are shown in the table below:

 
 Name                 Share Options granted   Total no. of options 
                                               over ordinary shares 
                                               now held 
 Peter Butterfield    1,250,000               5,804,803 
                     ----------------------  ---------------------- 
 Andrew Franklin      178,000                 2,903,000 
                     ----------------------  ---------------------- 
 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by person discharging managerial responsibilities.

 
 1     Details of the person discharging managerial 
        responsibilities/person closely associated 
 a)    Name                    Mr Peter Butterfield 
      ----------------------  ------------------------------------------------ 
 2     Reason for the notification 
      ------------------------------------------------------------------------ 
 a)    Position/status         Chief Executive Officer - Director 
      ----------------------  ------------------------------------------------ 
 b)    Initial notification    Initial Notification 
        /Amendment 
      ----------------------  ------------------------------------------------ 
 3     Details of the issuer, emission allowance market 
        participant, auction platform, auctioneer or 
        auction monitor 
      ------------------------------------------------------------------------ 
 a)    Name                    Alliance Pharma plc 
      ----------------------  ------------------------------------------------ 
 b)    Legal Entity            N/A 
        Identifier 
      ----------------------  ------------------------------------------------ 
 4     Details of the transaction(s): section to be 
        repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; and 
        (iv) each place where transactions have been 
        conducted 
      ------------------------------------------------------------------------ 
 a)    Description             Ordinary shares of 1.0 pence each 
        of the financial        ISIN: GB0031030819 
        instrument, 
        type of instrument 
        Identification 
        code 
      ----------------------  ------------------------------------------------ 
 b)    Nature of the           Grant of Options 
        transaction 
      ----------------------  ------------------------------------------------ 
 c)    Currency                GBP 
      ----------------------  ------------------------------------------------ 
 d)    Price(s) and              Exercise Price        No. of share options 
        volume(s)                      (p) 
      ----------------------  --------------------  -------------------------- 
                                      81.6p                  1,250,000 
 ---------------------------  --------------------  -------------------------- 
 
 e)    Aggregated               Grant of 1,250,000 options to acquire 
        information              shares at GBP0.816 per share at 
        -Aggregated              an aggregate exercise price of GBP1,020,000 
        volume 
        - Price 
        - Aggregated 
        total 
      ----------------------  ------------------------------------------------ 
 f)    Date of the             5 October 2018 
        transaction 
      ----------------------  ------------------------------------------------ 
 g)    Place of the            London Stock Exchange, AIM 
        transaction 
      ----------------------  ------------------------------------------------ 
 
 
 1     Details of the person discharging managerial 
        responsibilities/person closely associated 
 a)    Name                    Mr Andrew Franklin 
      ----------------------  ---------------------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------------- 
 a)    Position/status         Chief Financial Officer - Director 
      ----------------------  ---------------------------------------------- 
 b)    Initial notification    Initial Notification 
        /Amendment 
      ----------------------  ---------------------------------------------- 
 3     Details of the issuer, emission allowance market 
        participant, auction platform, auctioneer or 
        auction monitor 
      ---------------------------------------------------------------------- 
 a)    Name                    Alliance Pharma plc 
      ----------------------  ---------------------------------------------- 
 b)    Legal Entity            N/A 
        Identifier 
      ----------------------  ---------------------------------------------- 
 4     Details of the transaction(s): section to be 
        repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; and 
        (iv) each place where transactions have been 
        conducted 
      ---------------------------------------------------------------------- 
 a)    Description             Ordinary shares of 1.0 pence each 
        of the financial        ISIN: GB0031030819 
        instrument, 
        type of instrument 
        Identification 
        code 
      ----------------------  ---------------------------------------------- 
 b)    Nature of the           Grant of Options 
        transaction 
      ----------------------  ---------------------------------------------- 
 c)    Currency                GBP 
      ----------------------  ---------------------------------------------- 
 d)    Price(s) and              Exercise Price       No. of share options 
        volume(s)                      (p) 
      ----------------------  -------------------  ------------------------- 
                                     81.6p                  178,000 
 ---------------------------  -------------------  ------------------------- 
 
 e)    Aggregated               Grant of 178,000 options to acquire 
        information              shares at GBP0.816 per share at 
        - Aggregated             an aggregate exercise price of GBP145,248 
        volume 
        - Price 
        - Aggregated 
        total 
      ----------------------  ---------------------------------------------- 
 f)    Date of the             5 October 2018 
        transaction 
      ----------------------  ---------------------------------------------- 
 g)    Place of the            London Stock Exchange, AIM 
        transaction 
      ----------------------  ---------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHUGGPPUUPRUBA

(END) Dow Jones Newswires

October 05, 2018 05:25 ET (09:25 GMT)